TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference

Rhea-AI Summary

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) will attend and present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Michael Dudley will discuss the company's RNA-based cancer treatments, focusing on its lead candidate, TTX-MC138, which aims to enter its First in Human clinical trial in 2022. The presentation is scheduled for January 10, 2022, at 7:00 AM ET and will be webcast, with an archived recording available for 90 days on TransCode's website.

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer. The Company plans to advance its lead therapeutic candidate, designed to treat metastatic disease, into its First in Human clinical trial in 2022. 

	Event:	H.C. Wainwright BioConnect Conference
	Date:	January 10-13, 2022
	Presentation:	January 10, 2022 at 7:00 AM ET
	Location:	https://journey.ct.events/view/b7fd5be4-0bbd-4246-ab9c-4392b2bd0c30

The presentation will be webcast and an archived recording will be available for 90 days in the Investors’ section of TransCode Therapeutics’ website.

About TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing other therapeutic candidates and diagnostic products related to its planned therapeutics business.

Forward-looking Statement

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing and outcome of expected regulatory filings, including the filing of an eIND for the planned first-in-human study of TTX-MC138, and statements concerning the timing and outcome of this study, including whether this study will demonstrate proof-of-concept, and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U. S. Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

For further information:
TransCode Therapeutics, Inc.
Tom Fitzgerald, CFO
tom.fitzgerald@transcodetherapeutics.com

FAQ

What is the date of TransCode's presentation at the H.C. Wainwright BioConnect Conference?

TransCode's presentation at the H.C. Wainwright BioConnect Conference is scheduled for January 10, 2022, at 7:00 AM ET.

What is the main focus of TransCode's presentation at the conference?

The focus of TransCode's presentation is on RNA-based scientific discoveries aimed at advancing cancer treatment.

When does TransCode plan to start its First in Human clinical trial?

TransCode plans to start its First in Human clinical trial for its lead candidate, TTX-MC138, in 2022.

Why is TTX-MC138 significant in cancer treatment?

TTX-MC138 is significant as it targets metastatic cancer, which is responsible for approximately 90% of all cancer deaths.

Will TransCode's presentation be available after the event?

Yes, TransCode's presentation will be webcast and an archived recording will be available for 90 days on their website.